CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: Cost effectiveness study

BMJ (Online)

Volumn 343, Issue 7834, 2011, Pages 1135-

  Kahn, James G ^a   Marseille, Elliot ^b   Moore, David ^c   Bunnell, Rebecca ^d,e   Were, Willy ^d   Degerman, Richard ^d   Tappero, Jordan W ^d,e   Ekwaru, Paul ^d   Kaharuza, Frank ^d   Mermin, Jonathan ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Health Strategies International   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CDC Uganda   (Uganda)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIMULATION; UGANDA; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS; UGANDA; VIRAL LOAD;

EID: 82755170549     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6884     Document Type: Article

References (28)

1. UNAIDS. 2010 report on the global HIV/AIDS epidemic. UNAIDS, 2010. www.cia.gov/library/publications/the-world-factbook/geos/ug.html.
2. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008;371:752-9. (Pubitemid 351297773)
3. Tweya H, Gareta D, Chagwera F, Ben-Smith A, Mwenyemasi J, Chiputula F, et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the 'Back-to-Care' project in Lilongwe, Malawi. Trop Med Int Health 2010;15(suppl 1):82-9.
4. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010;24:2263-70.
5. Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, Schuttner L, et al. Comparative outcomes of tenofovir- and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia. J Acquir Immune Defic Syndr 2011 Aug 18 (epub ahead of print).
6. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008;371:1443-51. (Pubitemid 351635534)
7. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004;18(suppl 3):S21-5. (Pubitemid 39037455)
8. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006;367:1870-2. (Pubitemid 43833194)
9. Dart Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010;375:123-31.
10. Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010;51:85-92.
11. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV and receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011;d6792.
12. Wikipedia. Tororo district government. http://en.wikipedia.org/wiki/ Tororo-District.
13. US Central Intelligence Agency: Africa-Uganda. World Factbook, 2010. www.cia.gov/library/publications/the-world-factbook/geos/ug.html.
14. Ministry of Health (MOH) (Uganda) and ORC Macro. Uganda HIV/AIDS sero-behavioural survey 2004-2005. Ministry of Health and ORC Macro, 2006.
15. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006;368:1587-94. (Pubitemid 44767594)
16. Pitter C, Kahn JG, Marseille E, Lule JR, McFarland DA, Ekwaru JP, et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J Acquir Immune Defic Syndr 2007;44:336-43. (Pubitemid 46328352)
17. Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 2009;7:229-43.
18. Disease Control Priorities Project. The global burden of disease. Oxford University Press, 2006.
19. Médecins Sans Frontières. Untangling the Web of ARV Price Reductions: a pricing guide for the purchase of ARVs for developing countries, 10th ed. MSF, 2007.
20. Murru M, Corrrado B, Odaga J, Ahairwe D, Akulu E, Bavcar A, et al. Costing health services in Lacor Hospital. Health Policy and Development Journal. Department of Health Sciences of Uganda Martyrs University, 2003:61-8.
21. Morgan MG, Henrion M, Small M. Uncertainty : a guide to dealing with uncertainty in quantitative risk and policy analysis. Cambridge University Press, 1990.
22. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010;54:258-68.
23. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006;296:679-90. (Pubitemid 44200639)
24. Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 2009;374:2080-9.
25. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006;355:1141-53. (Pubitemid 44394920)
26. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa - a primary data analysis. Cost Eff Resour Alloc 2006;4:20.
27. World Health Organization. Priority interventions: HIV/AIDS prevention, treatment and care in the health sector. WHO, 2010.
28. Edejer T, Baltussen T, Hutubessy R, Acharya A, Evans D, Murray C. Making choices in health: WHO guide to cost-effectiveness analysis. In: WHO guide to cost-effectiveness analysis. World Health Organization, 2003. www.who.int/choice/publications/p-2003- generalised-cea.pdf.